STOCK TITAN

SenesTech (SNES) Stock Price, News & Analysis

SNES NASDAQ
Published by Stock Titan Data refreshed

Why is SNES Stock Up Today?

11.71%
20 alerts
3.3x vol
15m delay

SenesTech, Inc. (SNES) recently hired Sandstrom Partners to advise on marketing and branding, describing the engagement as an effort to accelerate sales; it did not report realized sales gains. An October 26 Schedule 13D reports that investor Justin LeBeau owns approximately 5.4% of the company’s shares, including shares bought in the open market.

AI-generated explanation by Rhea-AI, written on at . How Rhea-AI works. Not financial advice.

Price Move History

Daily moves over 5%
65 252 sessions, October 27, 2025 to October 27, 2026
Largest daily move
+34% close of May 7, 2026
1-year change
-77.3% closing prices, October 27, 2025 to October 27, 2026
1-month change
+17.2% closing prices, September 25, 2026 to October 27, 2026

Company Description

SenesTech, Inc. (NASDAQ: SNES) is a biotechnology company focused on fertility control for managing animal pest populations. According to the company’s public statements, SenesTech is committed to creating healthier environments by humanely managing rodent populations through contraceptive technologies rather than traditional poisons. Its products are designed to integrate into integrated pest management (IPM) programs and to support cleaner cities, efficient businesses, and healthier communities with solutions that are humane, effective, and sustainable.

SenesTech describes itself as a pioneer in rodent birth control. The company developed ContraPest®, which it states is the first and only U.S. Environmental Protection Agency (EPA)–registered contraceptive for male and female rats. In addition, SenesTech has developed Evolve Rat and Evolve Mouse Birth Control products, which are characterized in company materials as EPA-designated minimum-risk contraceptives for rodents. These offerings are positioned as long-term, fertility-based tools for rodent population control.

The company reports that its Evolve-branded products are used in agricultural, commercial, municipal, and consumer settings. Press releases note deployments in urban programs, including municipal pilots in locations such as New York City, Chicago, Boston, Baltimore, Los Angeles County, San Francisco, and other cities, as well as community pilots like the Town of Swampscott’s firehouse and school initiative. SenesTech also highlights use by pest management professionals and availability through retail and e-commerce channels.

SenesTech’s business model, as reflected in its disclosures, centers on the development, manufacturing, and commercialization of fertility control baits for rodents. The company emphasizes that its products are intended to fit seamlessly into existing pest management programs and to reduce reliance on traditional rodenticides. In multiple communications, SenesTech describes its approach as addressing the root cause of infestations by reducing reproduction rather than increasing the death rate.

Within its product portfolio, the company identifies Evolve Rat Birth Control as a soft bait that targets rat reproduction and is described as non-lethal and non-poisonous. Company news indicates that Evolve Rat is widely deployed in agricultural, commercial, and municipal environments and is also marketed to homeowners and do-it-yourself consumers. Evolve Mouse is presented as a related fertility control product for mice, and ContraPest is positioned as an EPA-registered contraceptive for rats.

SenesTech’s public updates describe a multi-channel distribution strategy. The company reports revenue contributions from e-commerce platforms, municipal programs, brick-and-mortar retail partners, and pest management professionals. E-commerce channels mentioned in company releases include Amazon and several major retail websites. Retail distribution is described through partners such as Ace Hardware and wholesalers that serve thousands of retail locations. Municipal deployments and pilot programs are cited as another channel that can also support awareness and adoption across retail and e-commerce.

In addition to domestic activities, SenesTech references international partnerships and regulatory efforts. Company news highlights regulatory approvals and distribution arrangements in various countries, including an international distributor relationship with the Belize Raptor Center for Evolve Rat Birth Control, following approval by the Pesticides Control Board of Belize. SenesTech also notes regulatory processes and distribution agreements in other regions in its financial and operational updates.

SenesTech’s filings and press releases also describe its capital markets and financing activities. The company has entered into at-the-market (ATM) offering arrangements with a sales agent, registered additional shares under that program, and completed warrant inducement transactions that generated gross proceeds for working capital and general corporate purposes. These activities are documented in its Form 8-K filings and related prospectus supplements.

The company’s common stock is listed on The Nasdaq Stock Market LLC under the symbol SNES, as disclosed in multiple Form 8-K filings. SenesTech identifies its headquarters city as Surprise, Arizona in SEC filings, reflecting its corporate location. The company’s sector and industry classification align with manufacturing and pesticide and other agricultural chemical manufacturing, consistent with its focus on rodent fertility control products.

SenesTech’s public mission statements emphasize humane, proactive, and sustainable pest management. Across its communications, the company states that it aims to improve the health of the world and to protect people, property, and the planet through fertility-based rodent control. Its messaging underscores the goal of reducing secondary wildlife poisonings and environmental contamination associated with traditional rodenticides, while providing tools that can be incorporated into existing pest management practices.

Stock Performance

$0.7701
-7.99%
0.07
Last updated: October 28, 2026 at 09:55
-77.3%
Performance 1 year

SenesTech (SNES) closed at $0.8370 on October 27, 2026. Over the past 12 months, the price has lost 77.3%.

See what a $1,000 investment in SNES would be worth today

Average down calculator for SNES

SNES Metrics & Rankings

Price returns through October 27, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Insider Radar

Net Buyers
90-Day Summary
1,115,169
Shares Bought
0
Shares Sold
13
Transactions
Most Recent Transaction
GLENBROOK CAPITAL MANAGEMENT (10% Owner) bought 7,500 shares @ $0.80 on October 22, 2026

Insider buying activity at SenesTech over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

SenesTech generated $2.2M in revenue in FY2025, retaining a 62.5% gross margin, operating income reached -$6.5M, and net income was -$6.4M. Diluted earnings per share stood at -$1.95. The company generated -$5.8M in operating cash flow. The current ratio was 12.61, measuring current assets divided by current liabilities.

$2.2M
Revenue (FY2025)
-$6.4M
Net Income (FY2025)
-$5.8M
Operating Cash Flow

Upcoming Events

NOV
09
November 9, 2026 - November 15, 2026 Earnings

Q3 2026 Results

Definitive third-quarter 2026 financial results planned for week of Nov 9, 2026; subject to quarter-end close and audit.
NOV
09
November 9, 2026 - November 15, 2026 Earnings

Definitive Q3 results

Definitive Q3 2026 results expected week of 2026-11-09–2026-11-15; preliminary revenue ~$1.1M, subject to quarter-end close.
APR
19
April 19, 2027 Regulatory

Nasdaq compliance deadline

Nasdaq gave notice Oct 20, 2026; SenesTech must regain $1.00+ bid by 2027-04-19 to avoid delisting; no immediate effect.
JUL
01
July 1, 2029 Financial

Option full vesting

Grant becomes fully vested on third anniversary of July 1, 2026 for 108,470 options at $1.19 exercise price; potential full dilution event.

SenesTech has 4 upcoming scheduled events. The next event, "Q3 2026 Results", is scheduled for November 9, 2026 (in 12 days). 2 of them are earnings releases or calls. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the SNES stock price.

Short Interest History

Last 12 Months

Short interest in SenesTech (SNES) currently stands at 27.4 thousand shares, down 10.6% from the previous reporting period, representing 0.5% of the float. Since October 2025, short interest has decreased by 53.7%.

Days to Cover History

Last 12 Months

Days to cover for SenesTech (SNES) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 1.8 days.

SNES Company Profile & Sector Positioning

SenesTech (SNES) operates in the Specialty Chemicals industry within the broader Basic Materials sector and is listed on the NASDAQ.

Investors comparing SNES often look at related companies in the same sector, including CN Energy Group Inc. (CNEY), BOLT PROJECTS HLDGS INC (BSLK), BioNexus Gene Lab Corp (BGLC), Bon Natural Life Limited (BON), and Northern Technologies International Corp. (NTIC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SNES's relative position within its industry.

Frequently Asked Questions

What is the current stock price of SenesTech (SNES)?

The current stock price of SenesTech (SNES) is $0.7701 as of October 28, 2026.

What is the market cap of SenesTech (SNES)?

The market cap of SenesTech (SNES) is approximately $4.2M. Learn more about what market capitalization means .

What is the revenue of SenesTech (SNES) stock?

The FY2025 revenue of SenesTech (SNES) is $2.2M, from its most recent completed fiscal year.

What is the net income of SenesTech (SNES)?

The FY2025 net income of SenesTech (SNES) is -$6.4M, from its most recent completed fiscal year.

What is the earnings per share (EPS) of SenesTech (SNES)?

The diluted earnings per share (EPS) of SenesTech (SNES) is -$1.95 for FY2025, its most recent completed fiscal year. Learn more about EPS .

What is the operating cash flow of SenesTech (SNES)?

The operating cash flow of SenesTech (SNES) is -$5.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

What is the gross margin of SenesTech (SNES)?

The gross profit margin of SenesTech (SNES) is 62.5% for FY2025, its most recent completed fiscal year. Learn about gross margins.

What is the current ratio of SenesTech (SNES)?

The current ratio of SenesTech (SNES), current assets divided by current liabilities, was 12.61 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

What is the gross profit of SenesTech (SNES)?

The gross profit of SenesTech (SNES) is $1.4M for FY2025, its most recent completed fiscal year.

What is the operating income of SenesTech (SNES)?

The operating income of SenesTech (SNES) is -$6.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

What does SenesTech, Inc. do?

SenesTech, Inc. focuses on managing animal pest populations, particularly rodents, through fertility control. The company develops and commercializes contraceptive bait products that are designed to integrate into integrated pest management programs and reduce reliance on traditional rodenticides.

What products does SenesTech offer for rodent control?

SenesTech identifies three main rodent fertility control products in its public materials: ContraPest®, described as the first and only U.S. EPA-registered contraceptive for male and female rats, and Evolve Rat and Evolve Mouse Birth Control, which it characterizes as EPA-designated minimum-risk contraceptives for rodents.

How is Evolve Rat Birth Control described by SenesTech?

According to company press releases, Evolve Rat Birth Control is a soft bait that targets rat reproduction. It is described as a non-lethal, non-poisonous product that reduces rat populations humanely and sustainably by addressing reproduction rather than relying solely on lethal control methods.

In what settings are SenesTech’s products used?

SenesTech states that its Evolve Rat product is deployed in agricultural, commercial, and municipal settings and is also marketed to homeowners and do-it-yourself consumers. Company news also references municipal pilot programs in various U.S. cities and community sites such as firehouses and schools.

How does SenesTech position its approach to pest management?

The company positions its approach as addressing the root cause of rodent infestations by decreasing the birth rate rather than increasing the death rate. It emphasizes humane, proactive, and sustainable fertility control that can fit into existing integrated pest management programs and reduce dependence on traditional poisons.

Where is SenesTech’s stock listed and what is its ticker symbol?

SenesTech’s common stock is listed on The Nasdaq Stock Market LLC under the ticker symbol SNES, as disclosed in multiple Form 8-K filings.

Does SenesTech operate internationally?

Company news indicates that SenesTech works with international partners and regulators. For example, it has reported that the Belize Raptor Center became an international distributor of Evolve Rat Birth Control after approval by the Pesticides Control Board of Belize, and it has referenced regulatory processes and distribution agreements in other countries.

What is SenesTech’s stated mission?

SenesTech’s mission statements in its press releases describe a commitment to improving the health of the world by humanely managing animal pest populations through fertility control. The company says it strives for cleaner cities, more efficient businesses, and healthier communities with products that are humane, effective, and sustainable.

How does SenesTech raise capital for its operations?

According to its Form 8-K filings, SenesTech has used at-the-market equity offerings and warrant inducement transactions to raise capital. These transactions involve selling common stock under an ATM agreement and entering into agreements with warrant holders to exercise existing warrants in exchange for new warrants, with proceeds intended for working capital and general corporate purposes.

What role do pest management professionals play in SenesTech’s business?

SenesTech reports that pest management professionals incorporate Evolve products into their service offerings. Company financial updates state that this channel contributes to revenue and that professionals use the fertility control attributes across a range of customer applications.